Voyager Therapeutics, Inc.
VYGR
$4.15
$0.030.73%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 36.49M | 40.37M | 31.32M | 42.58M | 66.96M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 36.49M | 40.37M | 31.32M | 42.58M | 66.96M |
| Cost of Revenue | 125.35M | 132.27M | 134.31M | 128.68M | 129.30M |
| Gross Profit | -88.86M | -91.90M | -102.99M | -86.10M | -62.34M |
| SG&A Expenses | 35.07M | 36.44M | 37.22M | 37.30M | 36.95M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 160.42M | 168.72M | 171.53M | 165.98M | 166.26M |
| Operating Income | -123.92M | -128.34M | -140.21M | -123.40M | -99.30M |
| Income Before Tax | -116.52M | -119.58M | -126.06M | -107.26M | -84.01M |
| Income Tax Expenses | 121.00K | 144.00K | 719.00K | 679.00K | 688.00K |
| Earnings from Continuing Operations | -116.64 | -119.72 | -126.78 | -107.93 | -84.69 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -116.64M | -119.72M | -126.78M | -107.93M | -84.69M |
| EBIT | -123.92M | -128.34M | -140.21M | -123.40M | -99.30M |
| EBITDA | -119.94M | -124.28M | -136.19M | -119.18M | -94.75M |
| EPS Basic | -1.98 | -2.04 | -2.17 | -1.85 | -1.46 |
| Normalized Basic EPS | -1.20 | -1.24 | -1.35 | -1.15 | -0.88 |
| EPS Diluted | -1.98 | -2.05 | -2.17 | -1.86 | -1.47 |
| Normalized Diluted EPS | -1.20 | -1.24 | -1.35 | -1.15 | -0.88 |
| Average Basic Shares Outstanding | 235.90M | 234.76M | 233.79M | 232.84M | 231.90M |
| Average Diluted Shares Outstanding | 235.90M | 234.76M | 233.79M | 232.84M | 231.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |